 |
|
|
| |
Baseline Clinical and Laboratory Parameters Associated With Clinical Benefits of Successful HCV Treatment With Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients
|
| |
| |
Reported by Jules Levin
DDW May 22-24 San Diego, CA
Robert S. Brown,1 K. Rajender Reddy,2 Jonathan Fenkel,3 Kevin Korenblat,4 Ziad H. Younes,5 Robert Herring,6 Di An,7 Anu Osinusi,7John McNally,7 Joseph Llewellyn,7, James Spellman,7 Diana M Brainard,7 John G. McHutchison,7 Michael P. Curry,8 Michael Charlton,9 Jacqueline O'Leary10
1Weill Cornell Medical College, New York, New York, USA; 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA; 3Thomas Jefferson University, Philadelphia, USA; 4Washington University School of Medicine in Saint Louis, Missouri, USA; 5Gastro One, Germantown, Tennessee, USA; 6Quality Medical Research, Nashville, Tennessee; 7Gilead Sciences, Inc., Foster City, California, USA; 8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 9Intermountain Medical Center, Murray, Utah, USA; 10Baylor University Medical Center at Dallas, Texas, USA
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
EASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)
EASL:Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
|
| |
|
|
|
|
|
